CBER/CDER Consolidation: 20 Staff Vacancies, Two ODE VI Clinical Divisions
Executive Summary
FDA is actively recruiting to replace 20 staffers who have left the Center for Biologics Evaluation & Research since plans to consolidate with CDER were announced a year ago
You may also be interested in...
Consolidated CDER/CBER INDs renumbered
The Center for Drug Evaluation & Research will assign new numbers to a group of INDs that were transferred from the Center for Biologics Evaluation & Research in 2003. The 2003 consolidation of the two centers created INDs with duplicate numbers (1"The Pink Sheet" Sept. 15, 2003, p. 14). To resolve the problem, INDs numbered below 14,000 submitted to CDER before the consolidation will be given new numbers by adding 80,000 to the original IND number...
Consolidated CDER/CBER INDs renumbered
The Center for Drug Evaluation & Research will assign new numbers to a group of INDs that were transferred from the Center for Biologics Evaluation & Research in 2003. The 2003 consolidation of the two centers created INDs with duplicate numbers (1"The Pink Sheet" Sept. 15, 2003, p. 14). To resolve the problem, INDs numbered below 14,000 submitted to CDER before the consolidation will be given new numbers by adding 80,000 to the original IND number...
FDA Oncology Drug Reviews Headed By Justice Under Revised Structure
Deputy director of FDA's biological oncology product review team Robert Justice will head the Division of Drug Oncology Products under the reorganization of the Office of New Drugs